For millions of people with type 1 diabetes, daily life means careful monitoring of blood sugar and multiple insulin injections. The disease happens when the body's own immune system destroys insulin-producing cells in the pancreas. Right now, treatment focuses on replacing the missing insulin, not the cells that make it. But researchers at Cedars-Sinai Medical Center in Los Angeles are testing something different: a therapy that could actually replace those lost cells permanently.
Scientists have started the first human study of a new cell therapy that uses immune-engineered, donor-derived insulin-producing cells. The work was presented at the International Society for Stem Cell Research 2026 Annual Meeting by Dr. Sonja Schrepfer, a physician and researcher at Cedars-Sinai and a guest professor at Uppsala University in Sweden.
The big challenge the team is tackling is immune rejection. When doctors transplant cells from a donor into a patient, the immune system usually attacks those foreign cells. To prevent that, patients currently need powerful drugs that suppress their immune system for life. These drugs come with serious side effects, including higher risk of infections and other health problems. Dr. Schrepfer and her team want to know if their approach can eliminate that need entirely.
The technique uses what researchers call "hypoimmune" engineering. Basically, scientists modify the donor cells so they can hide from the patient's immune system. The hope is that these protected cells can survive, produce insulin, and function normally without the patient needing to take immunosuppression drugs.
"Type 1 diabetes is still treated primarily by replacing insulin, not by replacing the insulin-producing cells that were lost," Dr. Schrepfer explained. "Our goal is to develop a cell replacement approach that can survive and function without chronic immunosuppression, with the long-term vision of providing a curative therapy for people with type 1 diabetes."
If this approach works, it could change lives. Patients might no longer face the daily burden of managing their disease with constant insulin injections and blood sugar checks. The findings could also open doors for other cell and tissue therapies, potentially helping people with different conditions beyond diabetes. Researchers still need to answer questions about how long the treatment lasts and whether it works safely in larger groups of patients. But this first human study marks a significant step toward a future where a functional cure for type 1 diabetes might actually be within reach.